Kamau Therapeutics is a clinical-stage company developing next-generation gene correction therapies using high-efficiency targeted gene integration. The company focuses on creating a new class of medicines designed to cure a range of serious and life-threatening diseases. Their work centers on delivering definitive, curative genetic treatments for patients with genetic disorders.
Funding
Funding not disclosed
Founders
Product
Problem
Many genetic diseases lack curative treatments, forcing patients to manage symptoms rather than address the underlying cause. Traditional gene therapies often suffer from limitations in specificity, efficiency, and long-term durability, hindering their potential to provide lasting cures.
Solution
Kamau Therapeutics is developing a next-generation gene correction platform based on homology-directed repair (HDR) to precisely correct genetic mutations at their source. The platform leverages CRISPR-Cas9 technology to cut pathologic mutations and paste the correct DNA sequence, restoring healthy cellular function. By delivering a high-fidelity ribonucleoprotein (RNP) complex and an adeno-associated virus (AAV) vector carrying the corrected DNA sequence into hematopoietic stem cells (HSCs), the technology harnesses the cell's own repair mechanisms to achieve durable genetic repair. This approach aims to provide one-time curative cell therapies for a range of serious and life-threatening genetic diseases. Their lead program, nulabeglogene autogedtemcel (nula-cel), is in clinical development for sickle cell disease, directly correcting the mutation in the beta-globin gene to restore normal adult hemoglobin.
Target Audience
The primary target audience includes patients with severe genetic diseases, particularly sickle cell disease, and the physicians who treat them, such as hematologists and gene therapy specialists.
Features
- High-fidelity homology-directed repair (HDR) for precise gene correction
- CRISPR-Cas9 system for targeted DNA cutting and pasting
- Ribonucleoprotein (RNP) complex for efficient and specific gene editing
- Adeno-associated virus (AAV) vector for delivering corrected DNA sequences
- Hematopoietic stem cell (HSC) based therapy for durable, long-term correction
- Ability to modify genetic material from 1bp up to 4000bp
- High on-target editing with minimal off-target effects